DGAP-News: Proteo, Inc. / Proteo Biotech AG: Elafin shortens intensive care after surgery for esophagus cancer
(firmenpresse) - DGAP-News: Proteo Biotech AG / Key word(s): Study/Research Update
Proteo, Inc. / Proteo Biotech AG: Elafin shortens intensive care after
surgery for esophagus cancer
23.02.2011 / 15:44
---------------------------------------------------------------------
Irvine, CA - Kiel, 23rd February 2011 - Proteo, Inc. (OTCBB: PTEO;
Freiverkehr Frankfurt and Berlin WKN: 925981) and its wholly-owned
subsidiary Proteo Biotech AG disclosed results of a Phase II clinical
trial on the candidate drug Elafin today.
The effect of Elafin on the postoperative inflammatory reaction occurring
in cancer patients whose esophagus has been removed was investigated at the
University Hospitals in Kiel, Münster and Munich. This serious operation
(esophagectomy), which lasts for several hours, carries the risk of
numerous specific complications that generally result in a prolonged period
of intensive care. The results of the trial show that intravenously
administered Elafin has a very clear positive effect on the period of
recovery: 63 percent of the Elafin treated patients required only one day
of intensive care. All patients in the placebo group needed several days of
postoperative intensive medical care.«These results have fully met our
optimistic expectations», commented Birge Bargmann, CEO of Proteo Biotech
AG.
Detailed results from this multicenter, blinded, randomized and
placebo-controlled trial are to be published in a scientific journal.
In January 2010, on recommendation of the European Medicines Agency (EMA),
the European Commission granted Proteo Biotech AG«orphan drug status»for
Elafin in the treatment of esophagus carcinoma.
Further information on the clinical development program for Elafin:
Proteo's pharmaceutical Elafin is a copy of a naturally occurring human
anti-inflammatory substance. It is a natural antagonist of the tissue
destroying enzymes (proteases) that participate in the inflammatory
mechanism of many diseases. Elafin's ability to block the enzymes that
cause these undesirable effects makes it a promising drug for the treatment
of, for example, inflammatory lung diseases and severe reperfusion injury.
The excellent tolerability of intravenously administered recombinant Elafin
has already been demonstrated convincingly in a Phase I clinical trial. In
addition to the clinical trial on esophagus carcinoma described above,
Proteo's licensing and development partner, Minapharm Pharmaceuticals SAE,
has initiated another Phase II clinical trial for the use of Elafin on
kidney transplant patients. This trial is concerned with the prevention of
acute organ rejection and chronic graft injury (allograft nephropathy). As
a further cooperation partner, the University of Edinburgh is initiating a
clinical trial to test Elafin in bypass operations after heart attacks.
This study is being supported by the Medical Research Council (MRC) and the
Chest, Heart and Stroke Scotland (CHSS) with 500,000 GBP.
About Proteo:
The company researches, develops and markets compounds for biological and
medical research as well as for use as pharmaceuticals. The main focus is
on anti-inflammatory drugs. The lead product is the human protease
inhibitor Elafin. Proteo intends to out-license selected indications and to
establish international strategic alliances in order to open up new fields
of application and for marketing. (www.proteo.de).
Forward-Looking Statements
Certain statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act of 1933
and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to
the safe harbor created by those rules. All statements, other than
statements of fact included in this release, including, without limitation,
statements regarding potential future plans and objectives of the company,
are forward-looking statements that involve risks and uncertainties. There
can be no assurance that such statements will prove to be accurate and
actual results and future events could differ materially from those
anticipated in such statements. Technical complications that may arise
could prevent the prompt implementation of any strategically significant
plan(s) outlined above. The company cautions that these forward looking
statements and risks and uncertainties involved are further qualified by
other factors including, but not limited to those set forth in the
company's Form 10-K filing and other filings with the United States
Securities and Exchange Commission. The company undertakes no obligation to
publicly update or revise any statements in this release, whether as a
result of new information, future events or otherwise.
Contact: Dr. Barbara Kahlke
Proteo Biotech AG
Am Kiel-Kanal 44
D-24106 Kiel
Email : info(at)proteo.de
Telephone: +49(0)431 8888462
Fax : +49(0)431 8888463
End of Corporate News
---------------------------------------------------------------------
23.02.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
113214 23.02.2011
Datum: 23.02.2011 - 15:44 Uhr
Sprache: Deutsch
News-ID 33285
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 262 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Proteo, Inc. / Proteo Biotech AG: Elafin shortens intensive care after surgery for esophagus cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
Proteo Biotech AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
